logo-loader
Anatara Lifesciences Ltd

Anatara Lifesciences to outline its new strategy in human health at Proactive CEO Sessions

Following the successful licencing of its animal health product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products.

Steven Lydeamore
The company’s chief executive officer Steven Lydeamore will address investors at the CEO Sessions

Anatara Lifesciences Ltd (ASX:ANR) is focused on its new business strategy in human health, and in particular the development and partnering of its GaRP dietary supplement.

The company will outline its progress and strategy during this month’s Proactive CEO Sessions. Chief executive officer Steven Lydeamore will present to investors at the Melbourne CEO Session on Tuesday, February 19.

Lydeamore has 26 years’ international experience in the pharmaceutical industry, working in Australia, USA and Canada. He brings a strong track record of successfully commercialising products on a global scale.

Anatara’s product candidate GaRP is an evidence-based dietary supplement aimed at restoring and maintaining gut health. It is well advanced in proof of concept studies.

With foundations built on strong and successful science, GaRP has been designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

 

Animal health to human health

In October 2018, Anatara had received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for its animal health product licensed to Zoetis Inc.

The animal health product Detach has the approved label, “To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets”.

Following the successful licencing of its first product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products.

Register for the CEO Sessions today to find out more.

Melbourne details, Tuesday, February 19, 2019

Also featuring at the event will be Kazia Therapeutics Ltd (ASX:KZA), Peninsula Energy Ltd (ASX:PEN) and AdAlta Ltd (ASX:1AD).

Quick facts: Anatara Lifesciences Ltd

Price: $0.26

Market: ASX
Market Cap: $12.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anatara Lifesciences Ltd named herein, including the promotion by the Company of Anatara Lifesciences Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Anatara Lifesciences transitions gut health focus from animals to humans

Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steven Lydeamore speaks to Proactive Investors about the healthcare company's renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).   Lydeamore says the biotech firm's...

on 22/3/19

2 min read